Please assess the completion status of the following clinical trial:

Trial Title: Prediction of Delayed Toxic Cardiomyopathy in Children

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
ANTHRA GROUP~Inclusion Criteria:~* Patients who were treated with anthracyclines for malignant disease between the ages of 0 and 18~* Patient aged 11 to 27 years~* Included in the SpeckleAnthra Study (NCT02893787)~* Discontinued chemotherapy for more than 6 years~* Patient in remission of malignant disease~* Enrolled in a social security plan~* Written informed consent from at least one legal representative for the minor patient/ Written informed consent for patients of legal age~Exclusion Criteria:~* Onset of active malignancy or recurrence of malignancy after the Speckle Anthra study that required resumption of chemotherapy or mediastinal radiotherapy.~* Chronic cardiac, pulmonary or muscular pathology of etiology other than secondary to anthracycline therapy~* For adult patients: subject under guardianship or curators~CONTROL GROUP~Inclusion Criteria:~* Control patient included in the Speckle Control study (NCT02056925)~* Had a cardiological consultation with echocardiography performed for a banal reason (heart murmur test, cardiological symptoms) and whose result was normal~* No chronic disease or long-term drug treatment~Exclusion Criteria:~* Refusal to participate in the study by the patient and/or parents or legal guardian after receipt of the study's information and non-objection note.

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 27 Years
- Healthy Volunteers: t

Study Arms:
- Anthra2 (Type: EXPERIMENTAL): Patient will have an echocardiography with speckle tracking analysis 5 years after the end of their participation to SpeckleAnthra study (NCT02893787)
- Control (Type: ACTIVE_COMPARATOR): Cardiac ultrasound analysis with speckle tracking of age- and sex-matched healthy patients in the Anthra2 group

Based on this trial design, predict the completion outcome and termination type (if applicable).